IBSA Institut Biochimique SA v. Accord Healthcare Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: IBSA Institut Biochimique SA (Switzerland), IBSA Pharma Inc. (Delaware), and Altergon SA (Switzerland)
  • Defendant: Accord Healthcare, Inc. (North Carolina)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:23-cv-00054, D.N.J., 04/19/2024
• Venue Allegations: Plaintiffs allege venue is proper in the District of New Jersey because Defendant derives substantial revenue from sales in the state, has purposefully availed itself of the state's laws, has previously litigated in the district, and has consented to jurisdiction and venue for this action.
• Core Dispute: Plaintiffs allege that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiffs' Tirosint®-SOL oral solution infringes three patents related to stable pharmaceutical formulations of levothyroxine and methods of their administration.
• Technical Context: The technology concerns liquid oral solutions of levothyroxine (T4), a thyroid hormone used to treat hypothyroidism, focusing on formulations that improve stability by preventing degradation into the more potent T3 hormone.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendant's submission of an ANDA containing Paragraph IV certifications. Defendant asserted in notice letters that the patents-in-suit are invalid, unenforceable, or will not be infringed by its proposed generic product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,537,538 - "High-Stability Packaged Solutions of T4 Thyroid Hormone"

The Invention Explained

• Problem Addressed: The patent describes the problem of instability in liquid T4 hormone solutions, where T4 can prematurely convert to T3, a significantly more potent hormone ʼ538 Patent, col. 2:15-29 This conversion creates dosing inaccuracies and a risk of overdosage for the patient ʼ538 Patent, col. 2:23-29 Previous formulations using alcohol were still subject to a "significant degree of instability" regarding this conversion ʼ538 Patent, col. 2:42-45
• The Patented Solution: The invention is an alcohol-free, water-glycerol solution of T4 hormone packaged in a specific multi-barrier container system ʼ538 Patent, abstract This system is designed to significantly reduce the premature conversion of T4 to T3 ʼ538 Patent, col. 2:49-53 The packaging consists of a primary low-density polyethylene (LDPE) plastic container which is then placed inside a sealed, multi-layer laminated sachet that provides a barrier to the external environment ʼ538 Patent, col. 2:65-col. 3:4
• Technical Importance: This approach sought to provide a liquid T4 formulation with enhanced shelf-life stability and dosage reliability, which is critical for a drug requiring precise, lifelong administration ʼ538 Patent, col. 1:59-63

Key Claims at a Glance

• The complaint asserts claims 1-8 Compl. ¶24
• Independent Claim 1 requires:
  • A ready-to-use pharmaceutical preparation of T4 thyroid hormone packaged in a single dose container.
  • The container is pre-filled with a liquid pharmaceutical composition "consisting essentially of" T4 hormone dissolved in an alcohol-free solution of 85% glycerol in water, with an optional T3 amount of less than 2.5%.
  • The single dose container is a "one-component LDPE plastic container."
  • The LDPE container is "placed in a sealed sachet consisting of laminated films made of a plurality of different materials" selected from a specified list including polyethylene, aluminum, and polyethylene terephthalate.
• The complaint does not explicitly reserve the right to assert dependent claims beyond those listed.

U.S. Patent No. 11,096,913 - "High-Stability Packaged Solutions of T4 Thyroid Hormone"

The Invention Explained

• Problem Addressed: Like its parent '538 Patent, the '913 Patent addresses the chemical instability of T4 hormone in liquid solutions, particularly the undesirable conversion to T3 during storage, which complicates accurate dosing ʼ913 Patent, col. 2:19-33
• The Patented Solution: The invention claims a pharmaceutical preparation comprising a T4 hormone dissolved in an "alcohol-free and preservative-free solution of 85% glycerol in water," contained within a single-dose plastic container ʼ913 Patent, claim 1 By eliminating both alcohol and preservatives, the formulation aims to improve stability and suitability for chronic use, while the single-dose container protects it from microbiological contamination ʼ913 Patent, col. 6:58-66
• Technical Importance: The invention provides a stable liquid T4 formulation that avoids preservatives, which can be beneficial for patients requiring long-term therapy who may have sensitivities ʼ913 Patent, col. 6:64-66

Key Claims at a Glance

• The complaint asserts claims 1-9 Compl. ¶31
• Independent Claim 1 requires:
  • A pharmaceutical preparation of T4 thyroid hormone.
  • Comprising a container pre-filled with a liquid pharmaceutical composition "consisting essentially of" T4 hormone.
  • The T4 is dissolved in an "alcohol-free and preservative-free solution of 85% glycerol in water."
  • The composition may optionally contain T3 in an amount less than 2.5%.
  • The container is a "single dose plastic container."
• The complaint does not explicitly reserve the right to assert dependent claims beyond those listed.

U.S. Patent No. 11,241,382 - "Administration Regimen of Compositions of T4 Thyroid Hormone with High Oral Absorption"

• Technology Synopsis: The patent addresses the problem that T4 hormone absorption is significantly reduced when administered close to a meal, leading to recommendations for patients to wait 30-60 minutes before eating, which can reduce compliance ʼ382 Patent, col. 2:13-28 ʼ382 Patent, col. 2:30-45 The invention is a method of treatment using an alcohol-free, water-glycerol T4 solution that can be administered within a shorter time interval from a meal (e.g., less than 30 minutes) without a clinically significant decrease in absorption ʼ382 Patent, col. 2:51-57
• Asserted Claims: Claims 1-20 Compl. ¶38 Independent claim 1 is a method of treating a disease associated with thyroid hormone deficiency.
• Accused Features: The complaint alleges that Defendant's sale and promotion of its product will induce infringement of the claimed method by instructing patients and healthcare providers to administer the drug in a manner that directly infringes Compl. ¶39

III. The Accused Instrumentality

Product Identification

• Defendant Accord Healthcare, Inc.'s proposed generic levothyroxine sodium oral solution, identified in ANDA No. 218008 ("Accord's Product") Compl. ¶11 Compl. ¶18

Functionality and Market Context

• Accord's Product is an oral solution of levothyroxine sodium intended for the U.S. market in various dosage strengths Compl. ¶18
• The complaint alleges that Accord's ANDA refers to and relies upon the New Drug Application for Plaintiffs' Tirosint®-SOL product and contains data intended to demonstrate the bioequivalence of Accord's Product to Tirosint®-SOL Compl. ¶19 The infringement action is premised on the allegation that Accord seeks approval to market this generic product prior to the expiration of the patents-in-suit Compl. ¶1
• No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed, element-by-element infringement analysis or include claim chart exhibits. The infringement allegations are based on the premise that Accord's Product, as a generic version of Tirosint®-SOL, will necessarily practice the claims of the patents-in-suit Compl. ¶1 Compl. ¶19

'538 Patent Infringement Allegations

'913 Patent Infringement Allegations

Identified Points of Contention

• Scope Questions: A central question for the '538 and '913 Patents will be whether the specific formulation and packaging of Accord's Product fall within the scope of the claims. This may involve disputes over the meaning of "consisting essentially of" and whether any unlisted excipients in Accord's Product materially alter the invention's properties. For the '538 Patent specifically, a factual question may arise as to whether Accord's packaging constitutes a "one-component LDPE plastic container" placed within the specified type of "sealed sachet."
• Technical Questions: For the '382 method patent, the dispute will likely focus on induced infringement. A key question will be whether the instructions for use on Accord's proposed product label will direct or encourage patients and physicians to administer the drug within the "less than 30 minutes" time window from a meal, as required by the claims.

V. Key Claim Terms for Construction

• The Term: "consisting essentially of" (from Claim 1 of the '538 Patent and Claim 1 of the '913 Patent)

  • Context and Importance: This transitional phrase is critical for determining the scope of the claimed formulation. Its construction will define whether Accord's Product avoids infringement by including any additional, unlisted ingredients (excipients). Practitioners may focus on this term because even minor differences in formulation are a common basis for non-infringement arguments in ANDA litigation.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patents' specifications do not explicitly define the term. A party arguing for a broader scope may contend that the phrase permits the inclusion of unlisted substances that do not materially affect the "basic and novel properties" of the invention, which the patents identify as high stability and reduced conversion of T4 to T3 ʼ538 Patent, col. 2:49-58 ʼ913 Patent, col. 4:51-58
    • Evidence for a Narrower Interpretation: A party arguing for a narrower scope may assert that the invention's stability is derived specifically from the minimalist formulation, and therefore the term "consisting essentially of" should permit only the listed components and standard impurities, precluding any other active or inactive ingredients.

• The Term: "preservative-free" (from Claim 1 of the '913 Patent)

  • Context and Importance: The definition of this term is central to infringement of the '913 Patent. A dispute may arise if Accord's Product contains an excipient that is not primarily a preservative but possesses some antimicrobial properties.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent does not define the term. A broader view may suggest the formulation is free only of substances formally recognized and listed as preservatives for a given regulatory purpose.
    • Evidence for a Narrower Interpretation: The specification notes that the "preservative-free formulation is particularly indicated for chronic use," suggesting the intent was to avoid any such agents entirely ʼ913 Patent, col. 6:64-66 This could support an argument that the term excludes any substance that imparts a preservative effect, regardless of its primary function.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Accord has knowledge of the patents and that its product is "especially adapted for a use that infringes" and has "no substantial non-infringing use," which supports a claim for contributory infringement of the '538 and '913 Patents Compl. ¶25 Compl. ¶32 For the '382 method patent, the complaint alleges that Accord's sale and marketing of its product would "intentionally induce others to use" it in an infringing manner Compl. ¶39
• Willful Infringement: The complaint does not use the word "willful" but requests a finding that the case is "exceptional" and an award of attorneys' fees under 35 U.S.C. § 285 for each count Compl. ¶28 Compl. ¶35 Compl. ¶43 The basis for these allegations appears to be Accord's knowledge of the patents, evidenced by its submission of Paragraph IV certification notice letters Compl. ¶¶20-21

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of compositional scope: does the phrase "consisting essentially of" permit the presence of any unlisted excipients in Accord's formulation, or is the claim limited to only the recited components of T4, glycerol, and water? The answer will likely define the infringement analysis for the product patents ('538 and '913).
• A second primary question will be one of induced infringement: for the '382 method patent, will the evidence, particularly Accord's proposed product labeling, demonstrate a specific intent to encourage patients to administer the drug in the claimed manner (i.e., within 30 minutes of a meal), or will the instructions be sufficiently equivocal to negate a finding of inducement?
• A third question concerns structural limitations: does Accord's specific packaging configuration meet the limitations of the '538 Patent, which requires both a "one-component LDPE plastic container" and an outer "sealed sachet" made of specific laminated films? Factual disputes over the construction and materials of the generic product's packaging may be central to this infringement analysis.